April is Oesophageal Cancer Awareness Month

Gastric and oesophageal cancers treatments



Immunotherapies are designed to boost the body’s own immune system to help fight the cancer.

One common type of immunotherapy is called a PD-1 inhibitor. PD-1 is a molecule on T cells (a type of immune system cell), which normally helps keep T cells from attacking other cells in the body. By blocking PD-1, these drugs boost the immune response against cancer cells, which shrink some tumours or slow their growth.

In December 2020, nivolumab became the first PD-1 inhibitor to be approved for use in oesophageal cancer in Europe. It is approved for use as a monotherapy treatment for patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma previously treated with chemotherapy.

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.